SHANGHAI and HONG KONG, Feb. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
Hence then, the article about antengene announces clinical collaboration with junshi biosciences to explore the synergistic potential of atg 037 oral cd73 inhibitor in combination with js207 pd 1 vegf bsab was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb) )
Also on site :
- Police: Two killed in shooting at West San Jose shopping center
- OpenAI COO says ‘we have not yet really seen AI penetrate enterprise business processes’
- Judge Rules That ICE Agents Violate the Fourth Amendment by Making Arrests While Masked